Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

por Spinosa-Guzman, S, Van de Casteele, T, De La Rosa, G, De Doncker, P
Publicado 2010

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

por Sekar, V, De La Rosa, G, Van de Casteele, T, Spinosa-Guzman, S, Vis, P, Hoetelmans, RMW
Publicado 2010

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults

por Orkin, C, DeJesus, E, Khanlou, H, Stoehr, A, Supparatpinyo, K, Van de Casteele, T, Lathouwers, E, Spinosa-Guzman, S
Publicado 2010